You are invited to attend a presentation, "Rebalancing the Immune System in Type 1 Diabetes Without Drug Therapy: The Promise of Regulatory T Cells" on Wednesday, May 18th, 6 p.m. at the UCSF Medical Center, 513 Parnassus Ave, Room N-225, San Francisco. [Event Details]
Former Center Director, Jeffrey Bluestone, PhD, continues to stay busy in his current position as UCSF Executive Vice Chancellor and Provost. He is helping to tackle the university’s financial crisis while continuing to maintain his lab in the Diabetes Center.
It has been ten years since Jeffrey Bluestone, PhD, was recruited from the University to Chicago to lead the Diabetes Center at UCSF as the AW and Mary Margaret Clausen Distinguished Professor in Metabolism and Endocrinology . By aggressively recruiting some of the most talented basic researchers in diabetes, and by serving as the driving force behind the Diabetes Center's innovative clinical research program, Dr. Bluestone has elevated the stature of the Diabetes Center -- making it one of the top diabetes research institutions in the world.
The body's immune system is supposed to "tolerate" itself and distinguish "self" from "non-self." Autoimmune diseases such as type 1 diabetes result from the breakdown of this system, causing immune cells to attack and destroy insulin-producing beta cells or "self." In the November issue of Nature Immunology, Brian Fife, PhD and collaborators including senior author Jeffrey Bluestone
Center Director Jeffrey Bluestone, PhD and his lab staff have been leading the way in exploring regulatory T cells. These cells are instrumental in suppressing an autoimmune response and attack on insulin-producing beta cells. In the July issue of Nature Immunology, this research team announced its most recent breakthrough -- how regulatory T cells sometimes shift from their usual protective state to a destructive state -- killing cells and causing autoimmune disease.
To take a promising drug to market, it costs on average $500 million. Academic research institutions such as UCSF excel in conducting basic research and early stage human clinical trials, however, for cost reasons it is important that promising therapies are picked up by private industry.